Pluri Inc. Logo

Pluri Inc.

Develops placenta-based cell therapeutics using a proprietary 3D cell-expansion platform.

PLUR | TA

Overview

Corporate Details

ISIN(s):
US72942G2030
LEI:
Country:
Israel
Address:
Park Building No. 5, 3508409 Haifa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company that researches, develops, and manufactures cell-based products and therapeutics. The company specializes in its proprietary 3D cell-expansion technology platform, which is used to create solutions for commercial use aimed at improving human well-being and sustainability. Pluri develops products from placenta-based cells for applications across the medical and pharmaceutical industries, often in collaboration with research partners and academic institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-17 02:42
Director's Dealing
Other Report or Announcement
English 244.9 KB
2025-10-17 02:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-10-17 02:40
Remuneration Information
Immediate Report
English 161.6 KB
2025-10-17 02:40
Foreign Filer Report
Immediate Report
English 36.4 KB
2025-10-08 18:02
Regulatory News Service
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 146.0 KB
2025-10-08 18:02
Foreign Filer Report
Pluri Subsidiary Coffeesai and Instituto del Cafe de Chiapas Announce Strategic…
English 36.5 KB
2025-09-23 17:54
Director's Dealing
Other Report or Announcement
English 152.3 KB
2025-09-23 17:54
Foreign Filer Report
Other Report or Announcement
English 36.5 KB
2025-09-18 03:08
Registration Form
Other Report or Announcement
English 729.3 KB
2025-09-18 03:08
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 315.7 KB
2025-09-18 02:33
Registration Form
Other Report or Announcement
English 36.4 KB
2025-09-18 02:31
Registration Form
Other Report or Announcement
English 317.6 KB
2025-09-18 02:31
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-09-18 01:48
Annual Report
Report of Periodic or Interim Report
English 4.1 MB

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Pluri Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Eisai Co., Ltd. Logo
A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.
Japan 4523
Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden ELIC
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden ELN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel ENLV
Enorama Pharma AB Logo
Develops & makes consumer nicotine products & medicated gums, offering private label solutions.
Sweden ERMA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea 183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea 446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden EQL
ERYTECH Pharma S.A. Logo
Developing phage therapies to combat antibiotic-resistant bacterial infections.
France ERYP

Talk to a Data Expert

Have a question? We'll get back to you promptly.